4.6 Article

Reduction of the therapeutic dose of silencing RNA by packaging it in extracellular vesicles via a pre-microRNA backbone

Journal

NATURE BIOMEDICAL ENGINEERING
Volume 4, Issue 1, Pages 52-68

Publisher

NATURE PUBLISHING GROUP
DOI: 10.1038/s41551-019-0502-4

Keywords

-

Funding

  1. Centre for Neuromuscular Disease
  2. University of Ottawa Brain and Mind Research Institute
  3. National Research and Engineering Council of Canada [436104]
  4. Quebec Consortium for Drug Discovery (CQDM Explore grant)
  5. ALS Association Treat Program [15-LGCA-290]
  6. Canadian Institutes of Health Research [PPP-141720]

Ask authors/readers for more resources

A small percentage of the short interfering RNA (siRNA) delivered via passive lipid nanoparticles and other delivery vehicles reaches the cytoplasm of cells. The high doses of siRNA and delivery vehicle that are thus required to achieve therapeutic outcomes can lead to toxicity. Here, we show that the integration of siRNA sequences into a Dicer-independent RNA stem-loop based on pre-miR-451 microRNA-which is highly enriched in small extracellular vesicles secreted by many cell types-reduces the expression of the genes targeted by the siRNA in the liver, intestine and kidney glomeruli of mice at siRNA doses that are at least tenfold lower than the siRNA doses typically delivered via lipid nanoparticles. Small extracellular vesicles that efficiently package siRNA can significantly reduce its therapeutic dose. Integrating silencing RNA into the backbone of a microRNA that is highly enriched in small extracellular vesicles reduces the therapeutic dose of the silencing RNA.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available